Specialist Updates 
Oncology

Alpha therapy a ‘viable option’ for metastatic castration-resistant prostate cancer

No serious side effects or treatment-related deaths were reported.
1
17 January 2024
Save

Targeted alpha therapy is safe and effective for treating metastatic castration-resistant prostate cancer when other anticancer agents have failed, show results from the largest trial to date.

International researchers say actinium-225 prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) has a “substantial antitumour effect”, with most treated patients experiencing a decline in prostate specific antigen (PSA) levels.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .